At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 783 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Placebo for Obesity and Overweight. Completed, enrolled 783 participants across 70 sites in 5 countries.
Detailed Summary
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either continued tirzepatide or switched to placebo. The study lasted about 2 years (25 visits).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight
CountriesArgentina, Brazil, Puerto Rico, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMar 2021
Primary CompletionApr 2023
Study CompletionMay 2023
TodayJul 2026
First PostedDec 9, 2020
Enrollment StartMar 29, 2021
Primary CompletionApr 25, 2023
Study CompletionMay 18, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.6 years ago
Interventions
Tirzepatidedrug
Administered SC
Placeboother
Administered SC